Skip to main content
SpringerLink
Log in

Historical Development of Monoclonal Antibody Therapeutics

  • Chapter
Therapeutic Antibodies

Part of the book series: Handbook of Experimental Pharmacology ((HEP,volume 181))

Since the first publication by Kohler and Milstein on the production of mouse monoclonal antibodies (mAbs) by hybridoma technology, mAbs have had a profound impact on medicine by providing an almost limitless source of therapeutic and diagnostic reagents. Therapeutic use of mAbs has become a major part of treatments in various diseases including transplantation, oncology, autoimmune, cardiovascular, and infectious diseases. The limitation of murine mAbs due to immunogenicity was overcome by replacement of the murine sequences with their human counterpart leading to the development of chimeric, humanized, and human therapeutic antibodies. Remarkable progress has also been made following the development of the display technologies, enabling of engineering antibodies with modified properties such as molecular size, affinity, specificity, and valency. Moreover, antibody engineering technologies are constantly advancing to enable further tuning of the effector function and serum half life. Optimal delivery to the target tissue still remains to be addressed to avoid unwanted side effects as a result of systemic treatment while achieving meaningful therapeutic effect.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 259.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 329.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Andrew P, Chapman PA, Spitali M, West S, Stephens S, King DJ (1999) Therapeutic antibody fragments with prolonged in vivo half-lives. Nat Biotechnol 17:780-783

    Article  CAS  Google Scholar 

  • Barbas CF 3rd, Hu D, Dunlop N, Sawyer L, Cababa D, Hendry RM, Nara PL, Burton DR (1994) In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity. Proc Natl Acad Sci USA 91:3809-3813

    Article  PubMed  CAS  Google Scholar 

  • Blanchard C, Mishra A, Saito-Akei H, Monk P, Anderson I, Rothenberg ME (2005) Inhibition of human interleukin-13-induced respiratory and oesophageal inflammation by anti-humaninterleukin-13 antibody (CAT-354). Clin Exp Allergy 35:1096-1103

    Article  PubMed  CAS  Google Scholar 

  • Blattman JN, Greenberg PD (2004) Cancer immunotherapy: a treatment for the masses. Science 305(5681):200-205

    Article  PubMed  CAS  Google Scholar 

  • Boder ET, Wittrup KD (1997) Yeast surface display for screening combinatorial polypeptide libraries. Nat Biotechnol 15:553-557

    Article  PubMed  CAS  Google Scholar 

  • Borghaei H, Schilder RJ (2004) Safety and efficacy of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin). Semin Nucl Med 34:4-9

    Article  PubMed  Google Scholar 

  • Boulianne GL, Hozumi N, Shulman MJ (1984) Production of functional chimaeric mouse/human antibody. Nature 312:643-646

    Article  PubMed  CAS  Google Scholar 

  • Cambridge G, Leandro M, Edwards J, Ehrenstein M, Salden M, Bodman-Smith M, Webster A (2003) Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum 48:2146-2154

    Article  PubMed  Google Scholar 

  • Carlos Vaccaro JZ, Ober RJ, Wardl ES (2005) Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels. Nat Biotechnol 23:1283-1288

    Article  PubMed  CAS  Google Scholar 

  • Carter P (2006) Potent antibody therapeutics by design. Nat Rev Immunol 6:343-357

    Article  PubMed  CAS  Google Scholar 

  • Chapman AP (2002) PEGylated antibodies and antibody fragments for improved therapy: a review. Adv Drug Deliv Rev 54:531-545

    Article  PubMed  CAS  Google Scholar 

  • Coiffier B, Haioun C, Ketterer N, Engert A, Tilly H, Ma D, Johnson P, Lister A, Feuring-Buske M, Radford JA, Capdeville R, Diehl V, Reyes F (1998) Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 92:1927-1932

    PubMed  CAS  Google Scholar 

  • Cosimi AB, Burton RC, Colvin RB, Goldstein G, Delmonico FL, LaQuaglia MP, Tolkoff-Rubin N, Rubin RH, Herrin JT, Russell PS (1981) Treatment of acute renal allograft rejection with OKT3 monoclonal antibody. Transplantation 32:535-539

    Article  PubMed  CAS  Google Scholar 

  • de Kruif J, Baker AB, Marissen WE, Kramer RA, Throsby M, Rupprecht CE, Goudsmit J. Crucell Holland BV, Leiden, (2007) A Human Monoclonal Antibody Cocktail as a Novel Component of Rabies Postexposure Prophylaxis. Annu Rev Med 58:359-368

    Article  PubMed  CAS  Google Scholar 

  • de Wildt RM, Mundy CR, Gorick BD, Tomlinson IM (2000) Antibody arrays for high-throughput screening of antibody-antigen interactions. Nat Biotechnol 18:989-994

    Article  PubMed  CAS  Google Scholar 

  • Dyer MJ (1999) The role of CAMPATH-1 antibodies in the treatment of lymphoid malignancies. Semin Oncol 26:52-57

    PubMed  CAS  Google Scholar 

  • Choy EHS, Smith1 BHM, Moss K, Lisi L, Scott DGI, Patel4 J, Sopwith M, Isenberg DA (2002) Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial. Rheumatology 41:1133-1137

    Article  PubMed  CAS  Google Scholar 

  • Eiermann W (2001) Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: pivotal trial data. Ann Oncol 12(Suppl 1):S57-S62

    Article  PubMed  Google Scholar 

  • Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katsikis P, Brennan FM, Walker J, Bijl H, Ghrayeb J et al (1993) Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum 36:1681-1690

    Article  PubMed  CAS  Google Scholar 

  • Francis RJ, Sharma SK, Springer C, Green AJ, Hope-Stone LD, Sena L, Martin J, Adamson KL, Robbins A, Gumbrell L, O’Malley D, Tsiompanou E, Shahbakhti H, Webley S, Hochhauser D, Hilson AJ, Blakey D, Begent RH (2002) A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours. Br J Cancer 9:600-607

    Article  CAS  Google Scholar 

  • Gardner K (2006) Cytokine storm and an anti-CD28 monoclonal antibody. N Engl J Med 355:2593-2594

    Article  Google Scholar 

  • Ghetie Vea (1997) Increasing the serum persistence of an IgG fragment by random mutagenesis. Nat Biotechnol 15:637-640

    Article  Google Scholar 

  • Gillies SD, Lan Y, Wesolowski JS, Qian X, Reisfeld RA, Holden S, Super M, Lo KM (1998) Antibody-IL-12 fusion proteins are effective in SCID mouse models of prostate and colon carcinoma metastases. J Immunol 160:6195-6203

    PubMed  CAS  Google Scholar 

  • Gillies SD, Reilly EB, Lo KM, Reisfeld RA (1992) Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells. Proc Natl Acad Sci USA 89:1428-1432

    Article  PubMed  CAS  Google Scholar 

  • Gillies SD, Young D, Lo KM, Foley SF, Reisfeld RA (1991) Expression of genetically engineered immunoconjugates of lymphotoxin and a chimeric anti-ganglioside GD2 antibody. Hybridoma 10:347-356

    Article  PubMed  CAS  Google Scholar 

  • Griffiths AD, Williams SC, Hartley O, Tomlinson IM, Waterhouse P, Crosby WL, Kontermann RE, Jones PT, Low NM, Allison TJ et al (1994) Isolation of high affinity human antibodies directly from large synthetic repertoires. Embo J 13:3245-3260

    PubMed  CAS  Google Scholar 

  • Hanes J, Pluckthun A (1997) In vitro selection and evolution of functional proteins by using ribosome display. Proc Natl Acad Sci USA 94:4937-4942

    Article  PubMed  CAS  Google Scholar 

  • Hinton PR, Johlfs MG, Xiong JM, Hanestad K, Ong KC, Bullock C, Keller S, Tang MT, Tso JY, Vasquez M, Tsurushita N (2004) Engineered human IgG antibodies with longer serum halflives in primates. J Biol Chem 279:6213-6216

    Article  PubMed  CAS  Google Scholar 

  • Harrison JL, Williams SC, Winter G, Nissim A (1996) Screening of phage antibody libraries. Methods Enzymol 267:83-109

    Article  PubMed  CAS  Google Scholar 

  • Holt LJ, Herring C, Jespers LS, Woolven BP, Tomlinson IM (2003) Domain antibodies: proteins for therapy. Trends Biotechnol 21:484-490

    Article  PubMed  CAS  Google Scholar 

  • Hoogenboom H (2005) Selecting and screening recombinant antibody libraries. Nat Biotechnol 23:1105-1116

    Article  PubMed  CAS  Google Scholar 

  • Hudson PHPJ (2005) Engineered antibody fragments and the rise of single domains. Nat Biotechnol 23:1126-1136

    Article  PubMed  CAS  Google Scholar 

  • Hwang WY, Foote J (2005) Immunogenicity of engineered antibodies. Methods 36:3-10

    Article  PubMed  CAS  Google Scholar 

  • Idusogie EE, Wong P, Presta LG, Gazzano-Santoro H, Totpal K, Ultsch M, Mulkerrin MG (2001) Engineered antibodies with increased activity to recruit complement. J Immunol 166:2571-2575

    PubMed  CAS  Google Scholar 

  • Jakobovits A, Moore AL, Green LL, Vergara GJ, Maynard-Currie CE, Austin HA, Klapholz S (1993) Germ-line transmission and expression of a human-derived yeast artificial chromosome. Nature 362:255-258

    Article  PubMed  CAS  Google Scholar 

  • Jones PT, Dear PH, Foote J, Neuberger MS, Winter G (1986) Replacing the complementaritydetermining regions in a human antibody with those from a mouse. Nature 321:522-525

    Article  PubMed  CAS  Google Scholar 

  • Kenanova V, Olafsen T, Crow DM, Sundaresan G, Subbarayan M, Carter NH, Ikle DN, Yazaki PJ, Chatziioannou AF, Gambhir SS, Williams LE, Shively JE, Colcher D, Raubitschek AA, Wu AM (2005) Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments. Cancer Res 65:622-631

    PubMed  CAS  Google Scholar 

  • Kohler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495-497

    Article  PubMed  CAS  Google Scholar 

  • Kreitman RJ (1999) Immunotoxins in cancer therapy. Curr Opin Immunol 11:570-578

    Article  PubMed  CAS  Google Scholar 

  • Kreitman RJ, Wilson WH, White JD, Stetler-Stevenson M, Jaffe ES, Giardina S, Waldmann TA, Pastan I (2000) Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol 18:1622-1636

    PubMed  CAS  Google Scholar 

  • Kress A (2002) Adalimumab - for use in the treatment of rheumatoid arthritis: clinical review. Abbott Laboratories Biologic Licensing Application, 1-136. Office of Therapeutics Research and Review; Division of Clinical Trial Design and Analysis; Immunology and Infectious Disease Branch

    Google Scholar 

  • Lazar GA, Dang W, Karki S, Vafa O, Peng JS, Hyun L, Chan C, Chung HS, Eivazi A, Yoder SC, Vielmetter J, Carmichael DF, Hayes RJ, Dahiyat BI (2006) Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci USA 103:4005-4010

    Article  PubMed  CAS  Google Scholar 

  • Linenberger ML (2005) CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance. Leukemia 19:176-182

    Article  PubMed  CAS  Google Scholar 

  • Lonberg N (2005) Human antibodies from transgenic animals. Nat Biotechnol 23:1117-1125

    Article  PubMed  CAS  Google Scholar 

  • Maas RA, Dullens HF, Den Otter W (1993) Interleukin-2 in cancer treatment: disappointing or (still) promising? A review. Cancer Immunol Immunother 36:141-148

    Article  PubMed  CAS  Google Scholar 

  • Marks J (2004) Antibody affinity maturation by chain shuffling. Methods Mol Biol 248:327-343

    PubMed  CAS  Google Scholar 

  • Robinson MK, Doss M, Shaller C, Narayanan D, Marks JD, Adler LP, Gonz ález Trotter DE, Adams GP (2005) Quantitative Immuno-Positron Emission Tomography Imaging of HER2-Positive Tumor Xenografts with an Iodine-124 Labeled Anti-HER2 Diabody. Cancer Res 65:1471-1478

    Article  PubMed  CAS  Google Scholar 

  • McWhirter JR, K.-R.A., Saven A, Maruyama T, Potter KN, Mockridge CI, Ravey EP, Qin F, Bowdish KS, Alexion Antibody Technologies I (2006) Antibodies selected from combinatorial libraries block a tumor antigen that plays a key role in immunomodulation. Proc Natl Acad Sci USA 1003:1041-1046

    Google Scholar 

  • Meeker TC, Lowder J, Maloney DG, Miller RA, Thielemans K, Warnke R, Levy R (1985) A clinical trial of anti-idiotype therapy for B cell malignancy. Blood 65:1349-1363

    PubMed  CAS  Google Scholar 

  • Morris PJ, Russell N (2006) Alemtuzumab (Campath-1H): a systematic review in organ transplantation. Transplantation 81:1361-1367

    Article  PubMed  Google Scholar 

  • Neri D, Carnemolla B, Nissim A, Leprini A, Querze G, Balza E, Pini A, Tarli L, Halin C, Neri P, Zardi L, Winter G (1997) Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform. Nat Biotechnol 15:1271-1275

    Article  PubMed  CAS  Google Scholar 

  • Nissim A, Hoogenboom HR, Tomlinson IM, Flynn G, Midgley C, Lane D, Winter G (1994) Antibody fragments from a ‘single pot’ phage display library as immunochemical reagents. Embo J 13:692-698

    PubMed  CAS  Google Scholar 

  • Padlan EA (1991) A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties. Mol Immunol 28:489-498

    Article  PubMed  CAS  Google Scholar 

  • Reichmann L, Clark M, Waldmann H, Winter G (1988) Reshaping human antibodies for therapy. Nature 332(6162):323-327

    Article  Google Scholar 

  • Shawler DL, Bartholomew RM, Smith LM, Dillman RO (1985) Human immune response to multiple injections of murine monoclonal IgG. J Immunol 135:1530-1535

    PubMed  CAS  Google Scholar 

  • Shields RL et al. (2001) High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and design of IgG1 variants with improved binding to the FcγR. J Biol Chem 276:6591-6604

    Article  PubMed  CAS  Google Scholar 

  • Silacci M, Brack S, Schirru G, Marlind J, Ettorre A, Merlo A, Viti F, Neri D (2005) Design, construction, and characterization of a large synthetic human antibody phage display library. Proteomics 5:2340-2350

    Article  PubMed  CAS  Google Scholar 

  • Tao MH, Levy R (1993) Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma. Nature 362:755-758

    Article  PubMed  CAS  Google Scholar 

  • Throsby M, Geuijen C, Goudsmit J, Bakker AQ, Korimbocus J, Kramer RA, Clijsters-van der Horst M, de Jong M, Jongeneelen M, Thijsse S, Smit R, Visser TJ, Bijl N, Marissen WE, Loeb M, Kelvin DJ, Preiser W, ter Meulen J, de Kruif J (2006) Isolation and characterization of human monoclonal antibodies from individuals infected with West Nile Virus. J Virol 80(14):6982-6992

    PubMed  Google Scholar 

  • Vaughan TJ, Williams AJ, Pritchard K, Osbourn JK, Pope AR, Earnshaw JC, McCafferty J, Hodits RA, Wilton J, Johnson KS (1996) Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library. Nat Biotechnol 14:309-314

    Article  PubMed  CAS  Google Scholar 

  • von Mehren M, Adams G, Weiner LM (2003) Monoclonal antibody therapy for cancer. Annu Rev Med 54:343-369

    Article  PubMed  CAS  Google Scholar 

  • Wahl R (2005) Tositumomab and (131)I therapy in non-Hodgkin’s lymphoma. J Nucl Med 46(Suppl 1):128S-140S

    PubMed  CAS  Google Scholar 

  • Ward S, Mandez C, Vaccaro C, Zhou J, Tang Q, Ober RJ (2005) From sorting endosomes to exocytosis: association of Rab4 and Rab11 GTPases with the Fc receptor, FcRn, during recycling. Mol Biol Cell 16:2028-2038

    Article  PubMed  CAS  Google Scholar 

  • Weinblatt E, Ketystone C, Furst DE et al (2003) Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate. The ARMADA Trial. Arthritis Rheum 48:35-45

    Article  PubMed  CAS  Google Scholar 

  • Winter G, G.A., Hawkins RE, Hoogenboom HR (1994) Making antibodies by phage display technology. Annu Rev Immunol 12:433-455

    Article  PubMed  CAS  Google Scholar 

  • Wu AM, Senter P (2005) Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol 23:1137-1146

    Article  PubMed  CAS  Google Scholar 

  • Zhang W, Feng J, Li Y, Guo N, Shen B (2005) Humanization of an anti-human TNF-a antibody by variable region resurfacing with the aid of molecular modeling. Mol Immunol 42:1445-1451

    Article  PubMed  CAS  Google Scholar 

  • Zhao L, Rai SK, Grosmaire LS, Ledbetter JA, Fell HP (1999) Construction, expression, and characterization of anticarcinoma sFv fused to IL-2 or GM-CSF. J Hematother Stem Cell Res 8: 393-399

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Bone and Joint Research Unit, William Harvey Research Institute, Barts and The London, Queen Mary's School of Medicine and Dentistry, University of London, Charterhouse Square, EC1M 6BQ, London, UK

    A. Nissim & Y. Chernajovsky

Authors
  1. A. Nissim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Y. Chernajovsky
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. ARC Chair of Rheumatology, Centre Lead Bone & Joint Research Unit, Queen Mary's School of Medicine & Dentistry John Vane Science Centre, Charterhouse Square, EC1M 6BQ, London, UK

    Yuti Chernajovsky

  2. Bone & Joint Research Unit, Queen Mary's School of Medicine & Dentistry John Vane Science Centre, Charterhouse Square, EC1M 6BQ, London, UK

    Ahuva Nissim

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Nissim, A., Chernajovsky, Y. (2008). Historical Development of Monoclonal Antibody Therapeutics. In: Chernajovsky, Y., Nissim, A. (eds) Therapeutic Antibodies. Handbook of Experimental Pharmacology, vol 181. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-73259-4_1

Download citation

Publish with us

Policies and ethics

Search

Navigation